HCC I/II approval to extend

  • 08:59

Immunicum AB (publ) announced today that the Swedish Medical Products Agency and the Ethics Committee has approved that the phase I/II-study in liver cancer may be extended by up to six patients who will receive INTUVAX in combination with first-line treatments.

Read the press release here: Press release 151216 – HCC I-II approval for continuation